Carmot
Chemotype Evolution is a patent pending technology that was invented by Drs. Stig K. Hansen and Daniel A. Erlanson while they were working at Sunesis Pharmaceuticals. Carmot Therapeutics was founded by Drs. Hansen and Erlanson in 2008 with the goal of commercializing and further developing the technology. Carmot has licensed the technology and fragment libraries from Sunesis, and Carmot is in the process of further expanding the capabilities of Chemotype Evolution.